Drug Profile
Amlodipine/rosuvastatin - Alvogen Korea
Alternative Names: C1 R212+C2 R212; C1-R212/C2-R212; DP-R212Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Alvogen Korea
- Class Amines; Antihyperlipidaemics; Antihypertensives; Carboxylic acids; Chlorobenzenes; Dihydropyridines; Esters; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Hyperlipidaemia (In volunteers) in South Korea (PO)
- 12 Sep 2023 Discontinued - Preclinical for Hypertension (In volunteers) in South Korea (PO)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hyperlipidaemia(In volunteers) in South Korea (PO)